In late January, AstraZeneca announced a $15B investment in China through 2030, expanding R&D on Chinese soil with more manufacturing, and a focus on cell therapies and radioconjugates. The expansion builds on AstraZeneca’s long-running China footprint, which began in 1993 and currently runs two R&D centers in Shanghai and Beijing.
In this issue: From Generics to Innovation — Five Growth Stats — Company Radar — Rise & Constraints
